JP2022520106A5 - - Google Patents
Info
- Publication number
- JP2022520106A5 JP2022520106A5 JP2021547416A JP2021547416A JP2022520106A5 JP 2022520106 A5 JP2022520106 A5 JP 2022520106A5 JP 2021547416 A JP2021547416 A JP 2021547416A JP 2021547416 A JP2021547416 A JP 2021547416A JP 2022520106 A5 JP2022520106 A5 JP 2022520106A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- acid sequence
- car
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806632P | 2019-02-15 | 2019-02-15 | |
| US62/806,632 | 2019-02-15 | ||
| US201962815961P | 2019-03-08 | 2019-03-08 | |
| US62/815,961 | 2019-03-08 | ||
| US201962924151P | 2019-10-21 | 2019-10-21 | |
| US62/924,151 | 2019-10-21 | ||
| PCT/US2020/018441 WO2020168298A2 (en) | 2019-02-15 | 2020-02-14 | Lym-1 and lym-2 antibody compositions and improved car constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520106A JP2022520106A (ja) | 2022-03-28 |
| JP2022520106A5 true JP2022520106A5 (https=) | 2023-02-21 |
Family
ID=72044910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547416A Pending JP2022520106A (ja) | 2019-02-15 | 2020-02-14 | Ｌｙｍ－１およびｌｙｍ－２抗体組成物ならびに改善されたｃａｒ構築物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11667715B2 (https=) |
| EP (1) | EP3924387A4 (https=) |
| JP (1) | JP2022520106A (https=) |
| KR (1) | KR20210118945A (https=) |
| CN (1) | CN113710703A (https=) |
| AU (1) | AU2020221324A1 (https=) |
| BR (1) | BR112021015676A2 (https=) |
| CA (1) | CA3129501A1 (https=) |
| IL (1) | IL285463A (https=) |
| MX (1) | MX2021009744A (https=) |
| SG (1) | SG11202108655TA (https=) |
| WO (1) | WO2020168298A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201913697D0 (en) * | 2019-09-23 | 2019-11-06 | King S College London | DAP10/DAP12 fusion polypeptides |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4724212A (en) | 1985-05-24 | 1988-02-09 | Northwestern University | Murine hybridoma Lym-2 and diagnostic antibody produced thereby |
| US4724213A (en) | 1985-05-24 | 1988-02-09 | Northwestern University | Murine hybridoma Lym-1 and diagnostic antibody produced thereby |
| ATE112172T1 (de) * | 1987-10-30 | 1994-10-15 | American Cyanamid Co | Targetformer von antitumor-methyltrithioagenzien. |
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| CA2518552A1 (en) | 2003-03-11 | 2004-09-23 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related disease |
| NZ544924A (en) * | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| WO2005058251A2 (en) | 2003-12-15 | 2005-06-30 | Dendreon Corporation | Hla-dr-specific antibodies, compositions and methods |
| EP1789087A4 (en) | 2004-08-20 | 2009-10-21 | Univ California | GENETICALLY MODIFIED ANTIBODY FRAGMENT WHICH LINKS TO ANTIGEN IRREVERSIBLELY |
| CN1331887C (zh) | 2004-08-20 | 2007-08-15 | 上海美恩生物技术有限公司 | 抗hla－dr10的淋巴瘤特异性嵌合单抗 |
| ES2665422T3 (es) * | 2005-03-03 | 2018-04-25 | Immunomedics Inc. | Anticuerpos L243 humanizados |
| WO2007058725A2 (en) | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| EP1957541A2 (en) * | 2005-11-21 | 2008-08-20 | Laboratoires Serono SA | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| EP2158318A2 (en) * | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| CN101525385B (zh) * | 2008-03-07 | 2013-09-11 | 苏州工业园区晨健抗体组药物开发有限公司 | 恶性淋巴瘤、自身免疫性疾病抗体药物的筛选及其制备方法和用途 |
| CA2740900C (en) | 2008-11-03 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP2817330B1 (en) | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US20140348744A1 (en) | 2013-05-24 | 2014-11-27 | Jacek K. Pinski | Compositions and methods for regulating cancer-related signaling pathways |
| CN105829349B (zh) | 2013-10-15 | 2023-02-03 | 斯克利普斯研究所 | 肽嵌合抗原受体t细胞开关和其用途 |
| KR101605421B1 (ko) | 2014-03-05 | 2016-03-23 | 국립암센터 | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 |
| JP2015057834A (ja) | 2014-10-03 | 2015-03-26 | 株式会社村田製作所 | 積層セラミックコンデンサ |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| JP2018509148A (ja) | 2015-03-11 | 2018-04-05 | セレクティスＣｅｌｌｅｃｔｉｓ | 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法 |
| AU2016243128A1 (en) | 2015-03-27 | 2017-11-02 | University Of Southern California | HLA-G as a novel target for CAR T-cell immunotherapy |
| WO2016160618A2 (en) | 2015-03-27 | 2016-10-06 | University Of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
| WO2016174652A1 (en) | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
| WO2016197064A1 (en) | 2015-06-04 | 2016-12-08 | Epstein Alan L | Lym-1 and lym-2 targeted car cell immunotherapy |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| WO2018154386A1 (en) | 2017-02-21 | 2018-08-30 | Eutilex Co., Ltd. | Hla-dr car-t compositions and methods of making and using the same |
-
2020
- 2020-02-14 CA CA3129501A patent/CA3129501A1/en active Pending
- 2020-02-14 EP EP20756019.4A patent/EP3924387A4/en not_active Withdrawn
- 2020-02-14 KR KR1020217028644A patent/KR20210118945A/ko not_active Ceased
- 2020-02-14 SG SG11202108655TA patent/SG11202108655TA/en unknown
- 2020-02-14 BR BR112021015676-3A patent/BR112021015676A2/pt not_active IP Right Cessation
- 2020-02-14 CN CN202080020167.8A patent/CN113710703A/zh active Pending
- 2020-02-14 AU AU2020221324A patent/AU2020221324A1/en not_active Abandoned
- 2020-02-14 JP JP2021547416A patent/JP2022520106A/ja active Pending
- 2020-02-14 MX MX2021009744A patent/MX2021009744A/es unknown
- 2020-02-14 WO PCT/US2020/018441 patent/WO2020168298A2/en not_active Ceased
-
2021
- 2021-08-09 IL IL285463A patent/IL285463A/en unknown
- 2021-08-13 US US17/402,300 patent/US11667715B2/en active Active
-
2023
- 2023-04-28 US US18/141,116 patent/US20240150470A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102710963B1 (ko) | 항b7-h3의 모노클로널 항체 및 그가 세포 치료 중에서의 응용 | |
| JP7335272B2 (ja) | キメラ抗原受容体 | |
| ES2843599T3 (es) | Receptor de antígeno quimérico | |
| JP6633081B2 (ja) | 細胞 | |
| EP3166968B1 (en) | Compositions and methods of chimeric autoantibody receptor t cells | |
| JP2024062986A (ja) | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 | |
| JP2024102286A (ja) | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 | |
| US20190336533A1 (en) | Chimeric antigen receptor and natural killer cells expressing same | |
| CA3090546A1 (en) | Chimeric antigen receptors targeting the tumor microenvironment | |
| KR20210056377A (ko) | 세포내 락테이트 농도를 조절하는 트랜스 대사 분자와 조합된 키메라 수용체 폴리펩타이드 및 이의 치료 용도 | |
| JP7723420B2 (ja) | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 | |
| JP2020500010A (ja) | 分泌性バリアント免疫調節タンパク質および改変細胞療法 | |
| CN110234343A (zh) | 用于治疗癌症的经工程改造t细胞 | |
| KR102475696B1 (ko) | 키메라 폴리펩티드 및 그의 세포 막 내 국재화를 변경시키는 방법 | |
| US20230130737A1 (en) | Multifunctional Heteromultimeric Constructs | |
| JP2021509820A (ja) | 線維芽細胞活性化タンパク質αを標的とする結合ユニットとその応用 | |
| KR20220082775A (ko) | 항-pd-1 항체 및 이의 용도 | |
| CN115917317A (zh) | 用于测定表达嵌合抗原的免疫细胞的体外肿瘤杀伤活性的基于细胞的测定法 | |
| CA3168878A1 (en) | Quantitative control of activity of engineered cells expressing universal immune receptors | |
| JP2022520106A5 (https=) | ||
| JP2021514360A (ja) | Ｔａｇ−７２を標的化するｔ細胞疾患処置 | |
| JP2024513485A5 (https=) | ||
| TW202548018A (zh) | 用於調節ｔ細胞之組成物及方法 | |
| JP2025531021A (ja) | 免疫細胞を検出する方法 | |
| KR20260018078A (ko) | 암을 치료하기 위한 표적으로서의 합성 암 항원 |